Coronavirus disease

"Leadership, Reinvented - How to Foster Empathy, Servitude, Diversity, and Innovation in the Workplace" Has Launched Globally

Retrieved on: 
Tuesday, March 9, 2021
Articles, Health, Zoonoses, Global health, Epidemiology, Pandemics, Virus, Coronavirus disease

Leadership, Reinvented offers an adaptive, practical guide on leading in the midst of crisis.

Key Points: 
  • Leadership, Reinvented offers an adaptive, practical guide on leading in the midst of crisis.
  • Based on his viral "Stop Managing, Start Leading" TED talk, Leadership, Reinvented makes the case that traditional leadership has been long overdue for reinvention.
  • Post-Virus Insights: A bold book for unprecedented times, Leadership, Reinvented was written during the COVID-19 pandemic, with the post-virus world in mind.
  • If you are interested in speaking with Hamza about Leadership, Reinvented please reach out to [email protected]

New nference COVID-19 Study and Online Tracker First to Produce Evidence of Increased COVID-19 Vaccinations on Decreased Viral Incidence by US Counties

Retrieved on: 
Tuesday, March 9, 2021
Medical specialties, Vaccination, Health, Articles, Vaccine, Virology, Coronavirus disease

The research presents, for the first time, epidemiological evidence linking increased vaccinations to declining new COVID-19 cases.

Key Points: 
  • The research presents, for the first time, epidemiological evidence linking increased vaccinations to declining new COVID-19 cases.
  • Now, we can say with some confidence, backed by data-driven analysis, in which counties the declines are potentially due to vaccination.
  • The study's rapid generation can be attributed to the vast experience of nference data scientists in triangulating and synthesizing difficult-to-manage data.
  • "This new resource can help make it clear to the public the effectiveness of vaccination in the campaign against COVID-19."

COVID-19 Diagnostics Market Outlook to 2027: By Sample Type; Product & Service Type; Test Type; Mode; End Use and Region - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 9, 2021
Infectious diseases, Health, Medical devices, Occupational safety and health, Coronavirus disease, Public health, Zoonoses, Health

The global COVID-19 diagnostics market size is expected to reach USD 23.67 billion by 2027, according to the study.

Key Points: 
  • The global COVID-19 diagnostics market size is expected to reach USD 23.67 billion by 2027, according to the study.
  • The report gives a detailed insight into current market dynamics and provides analysis on future market growth.
  • COVID-19 medical tests play an important role in management of coronavirus and thus helping in containing the virus infection.
  • The analyst has segmented the Covid-19 diagnostics market report on the basis of product & service, sample type, test type, mode, & end-use

Covid fatigue blamed for dramatic fall in number of smokers giving up according to www.OxfordOnlinePharmacy.co.uk research

Retrieved on: 
Tuesday, March 9, 2021
Health, Articles, Tobacco control, Health effects of tobacco, Drug rehabilitation, General practice, Smoking cessation, Coronavirus disease, No Smoking Day, Pharmacy

OXFORD, England, March 9, 2021 /PRNewswire/ -- Covid fatigue has been blamed for a dramatic fall in the number of smokers giving up ahead of National No Smoking Day (March 10th).

Key Points: 
  • OXFORD, England, March 9, 2021 /PRNewswire/ -- Covid fatigue has been blamed for a dramatic fall in the number of smokers giving up ahead of National No Smoking Day (March 10th).
  • According to www.OxfordOnlinePharmacy.co.uk , prescriptions for stop smoking aids soared at the start of lockdown one, with figures for March almost three times as high as in the previous two years.
  • According to Gale, the initial positive impact of COVID on lifestyle choices appears to have been overtaken by a sense of fatigue: "It has been a long winter.
  • www.oxfordonlinepharmacy.co.uk is part of the Frosts Pharmacy Group which also comprises two bricks and mortar chemists in Oxfordshire.

ExeVir Bio Announces New Publication from VIB Scientists Showing Potent and Broad Neutralizing Activity and Infection Protection Against SARS-COV, its Variants of Concern and Related Coronaviruses

Retrieved on: 
Tuesday, March 9, 2021
Health sciences, Health, Medical specialties, Zoonoses, Medical research, Antibodies, Animal virology, Virology, Antiviral drug, Neutralizing antibody, Coronavirus disease, Coronavirus

Torsten Mummenbrauer, CEO of ExeVir Bio, said: "Covid-19 vaccines will unquestionably be a cornerstone of controlling the pandemic, yet a significant population segment will also need treatments.

Key Points: 
  • Torsten Mummenbrauer, CEO of ExeVir Bio, said: "Covid-19 vaccines will unquestionably be a cornerstone of controlling the pandemic, yet a significant population segment will also need treatments.
  • Hence, passive antibody immunotherapy with potent and broadly neutralizing molecules like our XVR011, to prevent or suppress viral replication in the lower airways, should find an important place in rescuing Covid-19 patients."
  • Exevir's lead asset XVR011 is a single domain-based anti- Covid-19 antibody (VHH-Fc) optimized for stability, safety, broad neutralizing capability and excellent manufacturability.
  • ExeVir Bio is harnessing its VHH technology platform to generate robust antiviral therapies providing broad protection against viral infections, including coronaviruses.

ExeVir Bio Announces New Publication from VIB Scientists Showing Potent and Broad Neutralizing Activity and Infection Protection Against SARS-COV, its Variants of Concern and Related Coronaviruses

Retrieved on: 
Tuesday, March 9, 2021
Health sciences, Health, Medical specialties, Zoonoses, Medical research, Antibodies, Animal virology, Virology, Antiviral drug, Neutralizing antibody, Coronavirus disease, Coronavirus

Torsten Mummenbrauer, CEO of ExeVir Bio, said: "Covid-19 vaccines will unquestionably be a cornerstone of controlling the pandemic, yet a significant population segment will also need treatments.

Key Points: 
  • Torsten Mummenbrauer, CEO of ExeVir Bio, said: "Covid-19 vaccines will unquestionably be a cornerstone of controlling the pandemic, yet a significant population segment will also need treatments.
  • Hence, passive antibody immunotherapy with potent and broadly neutralizing molecules like our XVR011, to prevent or suppress viral replication in the lower airways, should find an important place in rescuing Covid-19 patients."
  • Exevir's lead asset XVR011 is a single domain-based anti- Covid-19 antibody (VHH-Fc) optimized for stability, safety, broad neutralizing capability and excellent manufacturability.
  • ExeVir Bio is harnessing its VHH technology platform to generate robust antiviral therapies providing broad protection against viral infections, including coronaviruses.

Sigyn Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

Retrieved on: 
Monday, March 8, 2021
Medical specialties, Immunology, Health, Medicine, Cytokine storm, Endocrine system, Coronavirus disease, Cytokine, Severe acute respiratory syndrome

Our focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome and not addressed with an approved therapy.

Key Points: 
  • Our focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome and not addressed with an approved therapy.
  • Sigyn Therapy is a novel blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream.
  • Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths.
  • This press release contains forward-looking statements of Sigyn Therapeutics, Inc. (Sigyn) that involve substantial risks and uncertainties.

Biomed Diagnostics Viral Transport Media for COVID-19 Now Available

Retrieved on: 
Monday, March 8, 2021
Medicine, Health, Medical equipment, Quality management, Quality management system, Medical device, ISO 13485, Severe acute respiratory syndrome, Food and Drug Administration, Coronavirus disease

Biomed has significantly increased production volume of two transport media devices:VTM-C19 and Saline Solution (.85%).Both formulations have been validated for the safe transport and preservation of specimens from patients being tested for SARS-CoV-2 (COVID-19), influenza A, and RSV.

Key Points: 
  • Biomed has significantly increased production volume of two transport media devices:VTM-C19 and Saline Solution (.85%).Both formulations have been validated for the safe transport and preservation of specimens from patients being tested for SARS-CoV-2 (COVID-19), influenza A, and RSV.
  • Both VTM-C19 and Saline Solution (.85%) are manufactured by Biomed in their ISO 13485:2016 compliant, FDA-registered production facility, in Oregon, USA.
  • Both are available through the US and Canada, listed with the FDA and Health Canada.
  • Biomed Diagnostics operates in compliance with FDA Quality System (QS) Regulation/Medical Device Good Manufacturing Practices (21 CFR, Part 820) in the manufacture of all products.

AXIM® Biotechnologies Successfully Completes Point-of-Care Clinical Trials on its Rapid COVID-19 Neutralizing Antibody Test

Retrieved on: 
Monday, March 8, 2021
Medical specialties, Antibodies, Neutralizing antibody, Coronavirus disease, Medicine, Health sciences, COVID-19 drug development, AbC-19 rapid antibody test, COVID-19 testing

The main goal of these studies was to identify the ability of operators to successfully utilize ImmunoPass to accurately measure each participants level of neutralizing antibodies.

Key Points: 
  • The main goal of these studies was to identify the ability of operators to successfully utilize ImmunoPass to accurately measure each participants level of neutralizing antibodies.
  • Study findings reveal that operators found ImmunoPass easy to use and that they encountered no issues in using the Companys test to measure participants COVID-19 neutralizing antibodies.
  • Founded in 2014, AXIM Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19).
  • AXIMs COVID-19 rapid neutralizing antibody test is the first rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells.

SARS-CoV-2 (COVID-19) Vaccine: Global Market Analysis & Forecast to 2026 by Technology and Region - ResearchAndMarkets.com

Retrieved on: 
Monday, March 8, 2021
Health, Infectious diseases, COVID-19 vaccines, COVID-19, Clinical trials, Health sciences, Medicine, Medical research, Vaccination, Adenoviridae, COVID-19 vaccine, Vaccine, Coronavirus disease, Johnson & Johnson COVID-19 vaccine

The "SARS-CoV-2 COVID Vaccine Market Analysis & Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "SARS-CoV-2 COVID Vaccine Market Analysis & Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
  • This report provides a comprehensive overview of the size of the SARS-CoV-2 (COVID-19) Vaccine market, segmentation of the industry (by geography and vaccine technology), key players and the vast potential of vaccines that are in clinical trials.
  • This analysis indicates that the global COVID-19 vaccine market was worth $59 billion in 2021.
  • The COVID vaccine industry is expected to then grow significantly at a CAGR of over 9% and reach $47.5 billion by 2026.